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The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) can serve as a
ligand for the peroxisome proliferator activator receptor-c (PPAR-c) and has been shown to inhibit cell proliferation,
and to induce differentiation and apoptosis in tumor cell lines. Bexarotene is an RXR-selective retinoid that can
induce apoptosis of mycosis fungoides (MF) and Se´zary syndrome (SS) cells. Since the PPAR-c and RXR receptors
can form heterodimers, we studied the effects of CDDO and its synergism with bexarotene on apoptosis in MF/SS
cell lines (MJ, Hut78, and HH) and freshly isolated peripheral blood lymphocytes (PBL) from SS patients with
circulating atypical T cells (CD4þCD26). CDDO treatment at 1–5 lM for 48 h caused a concentration-dependent
apoptosis in three MF/SS cell lines and patients’ PBL compared to vehicle controls. Bexarotene augmented CDDO-
induced apoptosis in these cells. PPAR-c was expressed but decreased by 47% in MJ, 42% in Hut78, and 77% in HH
cells following CDDO treatment. The anti-apoptotic protein bcl-xL, but not bcl-2, was decreased by 69% in MJ, 31%
in Hut78, and 59% in HH cells and caspase-3 was activated following CDDO treatment. Interestingly, the PPAR-c
antagonist T007 did not block CDDO-induced apoptosis, and the more potent PPAR-c agonist rosiglitazone
required much higher concentrations (450 lM) than CDDO to induce apoptosis in MF/SS cells. In summary, CDDO
induces apoptosis that is further enhanced by bexarotene and decreases the PPAR-c and bcl-xL proteins in MF/SS
cells. CDDO’s effects on MF/SS cells may be at least partly mediated through a PPAR-c-independent mechanism.
Our ﬁndings suggest the rationale for further investigation of the clinical potential of CDDO, either alone or in
combination with bexarotene for MF/SS patients.
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Cutaneous T cell lymphomas (CTCL) are a group of
lymphoproliferative disorders characterized by localization
of malignant T lymphocytes to the skin at presentation.
Mycosis fungoides (MF), the most common and indolent
form of CTCL, is characterized by patches, plaques or
tumors containing epidermotropic CD4þCD45ROþ helper/
memory T cells. Prognosis in tumor-stage MF is poor, with a
median survival of less than 40 months. Se´zary syndrome
(SS) is the leukemic form of CTCL, which presents with
erythroderma and is characterized by atypical cells in the
peripheral blood and by a peripheral blood T cell clone.
Se´zary syndrome is an aggressive disease with a poor
prognosis and a median survival of only 30 months (Duvic
and Cather, 2000; Siegel et al, 2000). Early MF can often be
controlled with skin directed or biological response modi-
fiers including topical steroids or retinoids, phototherapy,
topical chemotherapy, interferon, cytokines, extracorporeal
photopheresis, or total skin electron beam irradiation
(Apisarnthanarax and Duvic, 2001). Although partial and
complete remissions are achieved, subsequent relapses are
common. Alternative or complementary therapies, espe-
cially for advanced MF/SS, are needed. Dysregulated
apoptosis of skin-homing memory T cells is involved in
pathogenesis and therapeutic implications of MF/SS (Ka-
cinski and Flick, 2001; Meech et al, 2001). Pharmacological
modulation of apoptosis may provide new therapeutic
approaches for this disease.
The novel synthetic oleanane triterpenoid, 2-cyano-3,
12-dioxoolean-1, 9-dien-28-oic acid or CDDO is a multi-
functional molecule with promising clinical potential as a
chemopreventive agent and as a therapeutic agent for the
treatment of cancer (Suh et al, 1999). In vitro studies have
shown that CDDO induces cell differentiation, growth
inhibition, and apoptosis in human leukemia (Ito et al,
2000; Pedersen et al, 2002), osteosarcoma (Ito et al, 2001)
and breast cancer (Lapillonne et al, 2003) cell lines. The
structure of CDDO resembles a steroid hormone and other
isoprenoids. More recent studies have suggested that
CDDO is a ligand for the peroxisome proliferator activator
receptor-g (PPAR-g) (Wang et al, 2000).
PPAR-g is a member of the nuclear hormone receptor
superfamily and thus acts as a ligand-dependent transcrip-
tion factor controlling cellular differentiation, proliferation
Abbreviations: CDDO, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic
acid; CTCL, cutaneous T-cell lymphomas; 15d-PGJ2, 15-deoxy-
D12,14-Prostaglandin J2; MF, mycosis fungoides; PARP, poly (ADP-
Ribose) polymerase; PBL, peripheral blood lymphocytes; PI,
propidium iodide; PPAR-g, peroxisome proliferator activator
receptor-g; SS, Se´zary syndrome
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and apoptosis. After ligand binding, PPAR-g forms a
heterodimer with the retinoid X receptor (RXR) (Mangelsdorf
et al, 1995). We have previously demonstrated that an RXR
ligand, bexarotene, is effective in reducing the cutaneous
manifestations of MF/SS in both early and late stage
patients (Duvic et al, 2001). Bexarotene can also induce
apoptosis of MF/SS cell lines in vitro (Zhang et al, 2002).
Thus, induction of apoptosis may be one mechanism of
bexarotene action in the treatment of MF/SS patients.
In this study, we determined the independent and
potentially synergistic effects of CDDO and other PPAR-g
ligands and bexarotene on apoptosis induction as well as
gene expression in malignant MF/SS cell lines and freshly
isolated peripheral blood lymphocytes (PBL) from Se´zary
syndrome patients.
Results
Effect of CDDO on growth inhibition in MF/SS cells To
determine whether CDDO inhibits MF/SS cell growth, MJ,
Hut78, and HH cells were treated with or without 1, 2, and
5 mM CDDO for 48 h and their viability was evaluated by
CellTiter 96 AQ One Solution Cell Proliferation Assay. As the
concentration of CDDO increased from 1 to 5 mM over 48 h,
cell growth inhibition was significantly increased from 21%
to 72% (MJ), 23% to 70% (Hut78), and 12% to 59% (HH) in
a concentration-dependent manner compared with vehicle
controls (n¼3; po0.05), respectively (Fig 1). These results
demonstrated that CDDO is a potent inhibitor of MF/SS cell
growth.
Effect of CDDO on cell cycle and apoptosis in MF/SS
cells To determine whether growth inhibition of CDDO is
due to cell-cycle arrest and/or apoptosis in MF/SS cells,
MJ, Hut78, and HH cell lines were treated with or without 1,
2, and 5 mM CDDO for 48 h. As the concentration of CDDO
increased from 1 to 5 mM, the number of cells with sub-G1
populations increased from 15% to 58% (MJ), 10% to 56%
(Hut78), and 12% to 47% (HH) in a concentration-depen-
dent manner compared to vehicle control (n¼3; po0.05).
Increased numbers of cells in the sub-G1 population were
accompanied by a loss of cells in the G1, S, and G2/M
phases (Fig 2). It has been reported that cells with these
features are those dying of apoptosis (Nicoletti et al, 1991).
This indicated that all three cell lines undergo apoptosis
rather than cell-cycle arrest under CDDO treatment.
In parallel to the cell-cycle analysis, we investigated the
effect of CDDO on annexin V-binding, an early hallmark of
apoptosis, in MF/SS cells (Vermes et al, 1995). As the
concentration of CDDO increased from 1 to 5 mM for 48 h,
the number of cells stained for annexin V increased from
11% to 65% (MJ), 11% to 73% (Hut78), and 6% to 69%
(HH) in a concentration-dependent manner compared to
vehicle control (n¼ 3; po0.05). Similar results were also
seen in freshly isolated PBL from Se´zary syndrome patients
with circulating atypical T cells (Fig 3). These results were
consistent with analysis of cell-cycle distributions from
propidium iodide (PI) staining, further confirming that MF/SS
cells undergo apoptosis following CDDO treatment.
Synergistic effect of CDDO and bexarotene on apopto-
sis induction in MF/SS cells To determine whether CDDO
and bexarotene can synergize to induce apoptosis in MF/
SS cells, three cell lines and patients’ PBL were treated with
1 mM CDDO, 10 mM bexarotene, or their combination for 48
h. CDDO treatment alone increased the sub-G1 population
by 14% and annexin V binding by 20% compared with
vehicle control. Bexarotene alone increased sub-G1 by only
2% and annexin V binding by 3% over vehicle control. The
combination of CDDO and bexarotene increased the
percentage of cells in sub-G1 populations by 37% and
annexin V binding by 49% in the HH cell line (Fig 4). Similar
results were also seen in other cell lines and patients’ PBL
(not shown). The above observation possibly suggests that
a combination of CDDO and bexarotene has synergistic
pro-apoptotic effects in MF/SS cells.
Effect of CDDO on expression of apoptosis-associated
proteins in MF/SS cells To understand the mechanism of
CDDO-induced apoptosis, we examined the expression
of nuclear receptor PPAR-g, death receptor Fas/FasL, anti-
apoptotic proteins bcl-2 and bcl-xL, and caspase-3 and
poly (ADP-Ribose) polymerase (PARP) proteins in three MF/
SS cell lines (MJ, Hut78, and HH). Western blotting showed
that PPAR-g protein was expressed and was decreased by
47% in MJ, 42% in Hut78, and 77% in HH cells following
treatment with 2 mM CDDO for 48 h. Expression of Fas/FasL
proteins was not changed following CDDO treatment. Bcl-
xL, but not bcl-2 protein, was decreased by 69% in MJ,
31% in Hut78, and 59% in HH cells following CDDO
treatment. CDDO treatment was also associated with
caspase-3 activation and PARP cleavage as determined
by the decrease of procaspase-3 and appearance of 85 kDa
fragments in all three MF/SS cell lines (Fig 5).
Effect of other PPAR-c ligands and antagonist on
apoptosis in MF/SS cells To determine whether other
PPAR-g ligands also induce apoptosis in MF/SS cells, three
cell lines were treated with 15-deoxy-D12,14-Prostaglandin
Figure 1
CDDO treatment inhibits cell growth of MF/SS cells. Cells (5  104)
were aliquoted into a 96-well culture plate and grown in medium with or
without 1, 2, and 5 mM CDDO for 48 h. Cell viability was determined by
comparing untreated control (DMSO) to treated groups with the
CellTiter 96 AQueous One Solution Cell Proliferation Assay performed
in triplicate. Each point represented mean  SD of triplicate determi-
nations. Significantly different from DMSO control values (n¼3;
po0.05).
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J2 (15d-PGJ2) (1, 10, and 50 mM) and rosiglitazone (1, 10,
50, 100, and 200 mM) for 48 h. As the concentration of 15d-
PGJ2 increased from 10 to 50 mM, the number of HH cells
with annexin V binding increased from 67% to 94% in
a concentration-dependent manner over vehicle control
(Fig 6A). Rosiglitazone required much higher concentrations
(50–200 mM) than CDDO to induce annexin V binding by
3%–33% in the HH cell line (Fig 6B). Similar results were
also seen in MJ and Hut78 cell lines (not shown). Moreover,
T007, a PPAR-g-specific antagonist, did not block the
CDDO-induced apoptosis in three cell lines (Fig 7).
Discussion
Apoptosis is a genetically regulated form of cell death
characterized by specific morphologic and biochemical
changes that differ from necrosis (Kerr et al, 1972).
Apoptosis plays an important role in embryogenesis, aging,
and many diseases including cancer (Webb et al, 1997). The
anti-tumor actions of many chemotherapeutic agents have
been attributed to induction of apoptosis (Hickman, 1992).
In MF/SS, effective treatments such as phototherapy (Yoo
et al, 1996), photopheresis (Bladon and Taylor, 1999) and
rexinoids (Zhang et al, 2002) work through induction of T cell
apoptosis. In this study, we show for the first time that
CDDO causes apoptosis of MF/SS cells in association with
downregulation of bcl-xL. PPAR-g expressed in MF/SS cells
is suppressed following CDDO treatment. Importantly,
bexatotene augments CDDO-induced apoptosis in MF/SS
cells, suggesting synergism.
Apoptosis is a multistep process and increasing numbers
of genes have been identified that are involved in the control
or execution of apoptosis (Synderman, 2001). Caspases
play a crucial role in apoptosis. Among the 14 known
members of interleukin-1-converting enzyme family of
proteases, caspase-3 has been shown to be a key compo-
nent of the apoptotic machinery (Nunez et al, 1998).
Caspase-3 is activated in apoptotic cells and cleaves
several cellular proteins, including PARP. The cleavage of
PARP is used as a hallmark of apoptosis by various anti-
tumor agents (Duriez and Shah, 1997). In this study, we
show that CDDO treatment triggers apoptosis of three MF/
SS cell lines in association with caspase-3 activation and
PARP cleavage, implying that activation of caspase-3 is
involved in CDDO-induced apoptosis.
Figure2
CDDO treatment increases sub-G1 po-
pulation in MF/SS cells. Cells (1  106)
were treated with or without 1, 2, and 5
mM CDDO for 48 h. Cell-cycle distribution
was determined by DNA content analysis
with PI staining and flow cytometry. (A)
Each point represented the percent of
cell-cycle distributions with different DNA
content. (B) Histograms for cell cycle were
from analysis of MJ, Hut78, and HH cells
treated with 2 mM CDDO for 48 h. Results
were representative of one of three inde-
pendent experiments.
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Fas/FasL pair plays a critical role in regulating the life and
death of T lymphocytes (Varadachary and Salgame, 1998).
Fas is expressed on activated lymphocytes, but its
expression is decreased or lost in malignant MF/SS cells
(Dereure et al, 2000; Zoi-Toli et al, 2000; Zhang et al, 2002).
Impaired Fas/FasL apoptotic pathway may contribute to
the pathogenesis of MF/SS and could be manipulated
for therapeutic application. In this study, we found that
CDDO did not change the expression of Fas/FasL proteins
in MF/SS cells, suggesting that an apoptotic pathway
independent of Fas/FasL interactions may be involved in
CDDO-induced apoptosis.
The anti-apoptotic proteins, bcl-2 and bcl-xL, have been
demonstrated to play an important role in the regulation of
apoptosis and to inhibit the induction of apoptosis in
lymphocytes by a variety of signals (Reed, 1998). Expres-
sion of bcl-2 and bcl-xL is found in MF/SS cells and is
hypothersized to increase survival and resistance of MF/SS
cells against radiotherapy and extracorporeal photoche-
motherapy (Kanavaros et al, 1994; Dummer et al, 1995;
Osella-Aate et al, 2001; Zhang et al, 2002, 2003). Recent
studies have shown that bcl-2 and bcl-xL play a critical role
in controlling the activation of caspases by regulating
release of cytochrome c from mitochondria (Yang et al,
1997; Reed, 1998). This indicates that both proteins
function upstream of the caspase activation step in the cell
death pathway. In this study, we show that CDDO treatment
decreased the level of bcl-xL but not bcl-2 in all three cell
lines, suggesting that bcl-xL rather than bcl-2 is involved in
CDDO-induced apoptosis of MF/SS cells.
PPAR-RXR heterodimers can be activated by PPAR or
RXR ligands (Forman et al, 1997; Nolte et al, 1998), and
RXR-specific ligands markedly induce the binding of SRC-1
to PPAR-RXR heterodimers (Westin et al, 1998). Assembly
of this complex results in a large increase in transcriptional
activity. It has been shown that simultaneous activation of
both receptors can yield maximal anti-diabetic activation in
vivo (Mukherjee et al, 1997). Combinations of the PPAR-g
ligands with the RXR ligands were shown to markedly
decrease cell growth and induce monocytic differentiation
in myeloid leukemic HL-60 cells (Tontonoz et al, 1998).
Therefore, it was logical to try to enhance the effects of
PPAR-g ligands by combining them with the novel synthetic
RXR ligand bexarotene. In this study, we show for the first
time that PPAR-g is expressed and downregulated following
CDDO treatment in MF/SS cells. CDDO induced apoptosis
of MF/SS cells, and bexarotene enhanced the CDDO-
induced apoptosis. We previously reported that bexarotene
at clinically relevant concentrations (1–10 mM) requires
longer incubation (96 h) to induce apoptosis of MF/SS
cells. Furthermore, bexarotene at 24 and 48 h, prior to
causing apoptosis, induces some molecular events such as
downregulation of the expression of its cognate receptor,
RXR-a, in MF/SS cells (Zhang et al, 2002). This may give us
Figure 3
CDDO treatment increases annexin V
binding to MF/SS cells. Cells (1  106)
were treated with or without 1, 2, and 5
mM CDDO for 48 h. Annexin V binding was
carried out with the Annexin V-FITC
Detection Kit. (A) Each point represented
the percentage of both annexin Vþ PI
and annexin VþPIþ cells. (B), annexin V/
PI staining was analyzed from the Hut78
cell line and one Se´zary syndrome pa-
tient’s PBL. The lower right quadrant
showed annexin Vþ PI cells. The upper
right quadrant showed annexin VþPIþ
cells. Results were representative of one
of three independent experiments.
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a clue to explain why bexarotene alone for 48 h did not
induce apoptosis but has the synergy with CDDO in this
study. Further experiments for cross talk between RXR and
PPAR-g in MF/SS remain to be set up.
On the other hand, we tested other PPAR-g ligands 15d-
PGJ2 and rosiglitazone in inducing apoptosis of MF/SS
cells. Like CDDO, 15d-PGJ2, a natural PPAR-g ligand
(Forman et al, 1995), significantly induced apoptosis in
MF/SS cells. In contrast, the well-characterized synthetic
and high-affinity PPAR-g ligand, rosiglitazone (Lehmann
et al, 1995), required much higher concentrations (450 mM)
than CDDO to induce a lower level of apoptosis in MF/SS
cells. Moreover, the PPAR-g-specific antagonist T007 did
not block the CDDO-induced apoptosis in MF/SS cells. It
has been known that CDDO and 15d-PGJ2 recruit the co-
activator DRIP205 in myeloid leukemic cells, whereas other
synthetic potent PPAR-g ligands such as rosiglitazone do
not have this activity (Kodera et al, 2000; Tsao et al, 2001).
These findings suggest that CDDO-induced apoptosis is, at
least partially, mediated through PPAR-g-independent me-
chanisms in MF/SS cells.
Indeed, CDDO has been reported to have other PPAR-g-
independent activities, including suppression of inducible
nitric-oxide synthase and cyclooxygenase-2 (Suh et al,
1998; Honda et al, 2000), inhibition of NF-kB mediated gene
expression (Stadheim et al, 2002), and enhancement of
TGF-b/Smad signaling (Suh et al, 2003). Given the diverse
biological activities of CDDO, we are therefore left with the
conclusion that it is likely that another functional receptor
system (or systems) beyond PPAR-g remain to be identified
as CDDO target in MF/SS cells.
In conclusion, we demonstrated that CDDO induces
apoptosis of MF/SS cell lines and freshly isolated PBL from
Se´zary syndrome patients with circulating atypical T cells
(CD4þCD26). These events are associated with down-
regulation of PPAR-g and bcl-xL, and activation of caspase-
3. Bexarotene augments CDDO-induced apoptosis in MF/
SS cells. Our findings provide a rationale for the clinical
potential of CDDO, either alone or in combination with
bexarotene for MF/SS patients. Further experiments are
needed to confirm the results and clarify the molecular
details of their proapoptotic effects for clinical development.
Materials and Methods
Reagents CDDO was manufactured under the NIH RAID Program
under good manufacturing practice conditions and kindly provided
by Drs Edward A. Sausville and Michael B. Sporn. PPAR-g ligands
including rosiglitazone (BRL49653) and 15d-PGJ2 were purchased
from Cayman Chemical (Ann Arbor, Michigan). T0070907 (referred
thereafter as T007), a selective PPAR-g antagonist (Lee et al, 2002),
was synthesized and kindly provided by Dr Stephen H. Safe (Texas
A&M University, College Station, Texas). CDDO, rosiglitazone, and
T007 were dissolved in dimethyl sulfoxide (DMSO) to a stock
concentration of 10 mM and stored in 201C. Serial dilutions (1, 2,
5, 10, 50, 100, and 200 mM) were freshly made in RPMI 1640.
Bexarotene (LGD1069, 4-[1-(3, 5, 5, 8, 8-pentamethyl-5, 6, 7,
8-tetrahydro-2-naphthyl) ethenyl] benzoic acid) was obtained from
Ligand Pharmaceuticals Inc. (San Diego, California). A stock
solution of bexarotene at the concentration of 10 mM was
prepared in DMSO and stored at 201C in the dark.
Cells and cell culture Human CTCL cell lines MJ (G11), Hut78,
and HH obtained from American Type Culture Collection (Rockville,
Maryland) were derived from peripheral blood of patients with MF,
SS, and non-MF/SS aggressive CTCL, respectively (Gootenberg et
al, 1981; Popovic et al, 1983; Starkebaum et al, 1991). Samples of
peripheral blood were obtained for in vitro studies from three SS
patients with circulating atypical T cells (CD4þCD26). Samples
were obtained during routine diagnostic assessments after
informed consent was obtained in accordance with regulations
and protocols sanctioned by the Human Subjects Committee of
MD Anderson. PBL from these patients were isolated by
Vacutainer CPT (Becton Dicknson, San Jose, California). Cells
were grown in RPMI 1640 medium (Sigma Chemical, St Louis,
Missouri) supplemented with 10% heat-inactivated fetal bovine
serum (HyClone Laboratories, Logan, Utah), 2 mM HEPES, and 1%
penicillin–streptomycin in a humidified atmosphere with 5% CO2 at
371C.
Figure4
Synergistic effect of CDDO and bexar-
otene on apoptosis induction in MF/SS
cells. HH cells (1  106) were treated with
1 mM CDDO, 10 mM bexarotene, or their
combination for 48 h. Apoptosis was
measured by flow cytometry analysis of
sub-G1 and annexin V binding population.
(A), histograms for cell cycle were ana-
lyzed by PI staining and flow cytometry.
(B), annexin V/PI staining was analyzed by
flow cytometry. Results were representa-
tive of one of three independent experi-
ments.
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Cell viability Cell viability was measured by CellTiter 96 AQ One
Solution Cell Proliferation Assay (Goodwin et al, 1995) according to
the manufacturer’s instructions (Promega, Madison, Wisconsin).
Aliquots of 5  104 cells/well were distributed in 96-well micro-
plates (Falcon, Franklin Lakes, New Jersey) in 100 mL of medium
and incubated with 1, 2, and 5 mM CDDO for 48 h, then 20 mL of 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium, inner salt was added to each well and
incubated for an additional 4 h. The relative cell viability was
determined by ELISA with a 490 nm filter. Each experiment was
performed in triplicate, and repeated a minimum of three times.
Flow cytometry analysis of cell cycle MJ, Hut78, and HH cells
(1  106 cells) were incubated with or without 1, 2, and 5 mM
CDDO for 48 h. Cells were collected, washed with cold phosphate-
buffered saline (PBS), fixed in cold (201C) 100% ethanol, treated
with DNase-free RNase, and stained with 50 mg per mL PI.
Distribution of the cell-cycle phase by different DNA content was
determined with a FACScan flow cytometer (Becton Dickinson,
San Jose, California). For each sample, 10,000-gated events were
acquired. Analyses of cell-cycle distribution (including apoptosis:
sub-G1) were performed using Modfit software (Becton Dickinson).
Annexin V binding staining The analysis of annexin V binding
was carried out with an Annexin V-FITC Detection Kit I (PharMin-
gen, San Diego, California) according to the manufacturer’s
instructions. Briefly, three cell lines (MJ, Hut78, and HH) and
patients’ PBL were incubated with or without CDDO (1, 2, and
5 mM), bexarotene (10 mM), T007 (2 mM), 15d-PGJ2 (1, 10,
and 50 mM), rosiglitazone (1, 10, 50, 100, and 200 mM), or their
combinations for 48 h. Cells were collected, washed twice with
cold PBS, and centrifuged at 300 g for 5 min. Cells were
resuspended in 1  binding buffer at a concentration of 1  106
cells per mL, 100 mL of the solution was transferred to a 5 mL
culture tube, and 5 mL of annexin V-FITC and 5 mL of PI were
added. Cells were gently vortexed, and incubated for 15 min at
room temperature in the dark. Finally, 400 mL of 1  binding buffer
was added to each tube, and samples were analyzed by FACScan
flow cytometer (Becton Dickinson). For each sample, 10,000 un-
gated events were acquired. Annexin VþPI cells represent the
early apoptotic populations. Annexin VþPIþ cells represent either
late apoptotic or secondary necrotic populations.
Isolation of cytoplasmic and nuclear extracts Cells (5  106)
were washed with ice-cold PBS, harvested into 1 ml of PBS,
pelleted in a 1.5 mL microcentrifuge tube, and suspended in 400
mL of buffer A [10 mM HEPES (pH 7.9), 10 mM KCl, 1 mM EDTA,
1 mM EGTA, 1 mM DTT, and 1  protease inhibitor cocktail
‘‘complete mini’’ (Roche, Indianapolis, Indiana)]. After a 20 min
incubation on ice, the mixture was treated with a 24-G syringe for
five times and then centrifuged briefly to obtain the cytoplasmic
supernatant. The nuclear pellet was resuspended in 40–80 mL of
buffer C [10 mM HEPES (pH 7.9), 10 mM KCl, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT, 10% glycerol, and 1  protease inhibitor
cocktail ‘‘complete mini’’ (Roche)] and incubated at 41C with
shaking for 15 min. Protein concentrations were determined by the
Bradford dye-binding protein assay (Bio-Rad, Richmond, Califor-
nia) using bovine serum albumin as a standard.
Western blot analysis Cytoplasmic (20 mg) or nuclear (10 mg)
proteins were subjected to sodium dodecyl sulfate-polyacrylamide
gel (8–12%) electrophoresis (SDS-PAGE) and transferred onto
nitrocellulose membranes (Schleicher & Schuell, Dasse, Germany).
The membranes were blocked in 3% powdered milk in TBST [50
Figure5
Effect of CDDO on nuclear receptor and apoptosis-related
proteins in MF/SS cells. Cytoplasmic (20 mg) or nuclear (10 mg)
proteins from MJ, Hut78, and HH cells treated with 2 mM CDDO for 48 h
were fractionated by 8%–12% SDS-PAGE, transferred onto nitrocellu-
lose membranes and subjected to the ECL detection analysis. The
equivalent loading of proteins in each well was confirmed by actin. The
protein levels were quantified by AlphaEase 4.0 Imager. The amount of
PPAR-g and bcl-xL proteins from untreated controls was expressed as
100%. Lanes 1 and 2, MJ; Lanes 3 and 4, Hut78; Lanes 5 and 6, HH;
Lanes 1, 3, and 5, vehicle control (DMSO); Lanes 2, 4, and 6, 2 mM
CDDO; Lane 7, positive control for Fas protein.
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mM Tris (pH 7.5), 150 mM NaCl, 0.05% Tween 20], incubated with
primary antibody overnight at 41C in 3% powdered milk in TBST,
and washed extensively with TBST. They were incubated with
1:5000 peroxidase-conjugated anti-mouse or anti-rabbit second-
ary antibody (Jackson ImmunoResearch, West Grove, Pennsylva-
nia) for 1 h at room temperature. Monoclonal mouse anti-Fas and
anti-FasL were obtained from Transduction Laboratories (San
Diego, California). Monoclonal mouse anti-actin, anti-bcl-2, anti-
PPAR-g, anti-caspase-3 and anti-PARP, and polyclonal rabbit anti-
bcl-xL were obtained from Santa Cruz Biotechnology (Santa Cruz,
California). Immunoreactive bands were visualized by enhanced
chemiluminescence detection kit (Amersham, Buckinghamshire,
UK). The equivalent loading of proteins in each well was confirmed
by Ponceau staining and actin control. The protein levels were
quantified by an AlphaEase 4.0 Imager (Alpha Innotech Co., San
Leandro, California).
Statistical analysis All experiments were performed in triplicate
unless otherwise noted. Results were expressed as means  SD.
Statistical significance was evaluated by a two-tailed, paired,
Student’s t test, and po0.05 was considered as significant.
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Figure 7
Effect of the PPAR-c antagonist on CDDO-induced apoptosis in
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or their combination for 48 h. Apoptosis was measured by flow
cytometry analysis of annexin V and/or PI binding. Each point
represented the percentage of both annexin VþPI and annexin
VþPIþ cells. Results were representative of one of three independent
experiments.
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